Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger J R, Neckers L M
Tumor Cell Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4665-9. doi: 10.1073/pnas.90.10.4665.
We report experiments in the rat demonstrating the feasibility of intraventricular administration of oligodeoxynucleotides (ODNs) as a regional treatment approach to disorders within the central nervous system (CNS). Although we find little intrinsic nuclease activity in cerebrospinal fluid (CSF), phosphodiester ODNs are rapidly degraded by brain-associated alpha-exonuclease activity. Phosphorothioate ODNs, however, appear resistant to degradation in the CNS and, after intraventricular administration, we find they are cleared in a manner consistent with CSF bulk flow. Continuous infusion of ODN at 1.5 nmol/hr by miniosmotic pump can maintain micromolar concentrations of intact phosphorothioate ODN in CSF for at least 1 week without obvious neurologic or systemic toxicity. After infusion, extensive brain penetration and marked cellular uptake, especially by astrocytic cells, is demonstrated.
我们报告了在大鼠身上进行的实验,这些实验证明了脑室内给予寡脱氧核苷酸(ODNs)作为中枢神经系统(CNS)内疾病区域治疗方法的可行性。尽管我们发现脑脊液(CSF)中几乎没有内在的核酸酶活性,但磷酸二酯ODNs会被脑相关的α-核酸外切酶活性迅速降解。然而,硫代磷酸酯ODNs在中枢神经系统中似乎抗降解,脑室内给药后,我们发现它们以与脑脊液总体流动一致的方式清除。通过微型渗透泵以1.5 nmol/小时的速度持续输注ODN,可以在脑脊液中维持微摩尔浓度的完整硫代磷酸酯ODN至少1周,而没有明显的神经或全身毒性。输注后,证明其在脑内广泛渗透并被大量细胞摄取,尤其是星形细胞。